BridgeMD
This is a Global Study of Neoadjuvant-Adjuvant Durvalumab or Placebo and FLOT Chemotherapy Followed by Adjuvant Durvalumab or Placebo in Patients with Resectable Gastric and Gastroesophageal Cancer (GC/GEJC) (MATTERHORN)
EU CTIS ID: 2023-507338-26-00
What this study is testing
To compare Arm A relative to Arm B on event-free survival (EFS)
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patients with histologically documented gastric or gastroesophageal junction adenocarcinoma with resectable disease (Stage II or higher per AJCC 8th edition)
- Patients must have undergo radical surgery
- No prior anti-cancer therapy for the current malignancy
- World Health Organization (WHO)/ECOG PS of 0 or 1 at enrollment
- Adequate organ and marrow function
- Availability of tumor sample prior to study entry
You likely can't join if
- Patients with peritoneal dissemination or distant metastasis
- Patients with adenosquamous cell carcinoma, squamous cell carcinoma, or GI stromal tumor
- History of allogeneic organ transplantation
- Contra-indication to any of the study drugs
- Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab
See the full eligibility criteria
- Patients with histologically documented gastric or gastroesophageal junction adenocarcinoma with resectable disease (Stage II or higher per AJCC 8th edition)
- Patients must have undergo radical surgery
- No prior anti-cancer therapy for the current malignancy
- World Health Organization (WHO)/ECOG PS of 0 or 1 at enrollment
- Adequate organ and marrow function
- Availability of tumor sample prior to study entry
- Must have a life expectancy of at least 24 weeks
- Patients with peritoneal dissemination or distant metastasis
- Patients with adenosquamous cell carcinoma, squamous cell carcinoma, or GI stromal tumor
- History of allogeneic organ transplantation
- Contra-indication to any of the study drugs
- Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab
The study team makes the final eligibility decision.
Where it's taking place
- Japan
- United Kingdom
- Argentina
- Turkey
- Taiwan
- Chile
- Brazil
- Peru
- Russian Federation
- Korea, Democratic People's Republic of
- Canada
- United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Japan; United Kingdom; Argentina; Turkey; Taiwan; Chile and 6 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.